Limit profiles and uniqueness of ground states to the nonlinear Choquard equations

Consider nonlinear Choquard equations \begin{equation*} \left\{\begin{array}{rcl} -\Delta u +u & = &(I_\alpha*|u|^p)|u|^{p-2}u \quad \text{in } \mathbb{R}^N, \\ \lim_{x \to \infty}u(x) & = &0, \end{array}\right. \end{equation*} where $I_\alpha$ denotes Riesz potential and $\alpha \in (0, N)$. In this paper, we investigate limit profiles of ground states of nonlinear Choquard equations as $\alpha \to 0$ or $\alpha \to N$. This leads to the uniqueness and nondegeneracy of ground states when $\alpha$ is sufficiently close to $0$ or close to $N$.Comment: 18 pages, revised versio

Infinitely many solutions for semilinear nonlocal elliptic equations under noncompact settings

In this paper, we study a class of semilinear nonlocal elliptic equations posed on settings without compact Sobolev embedding. More precisely, we prove the existence of infinitely many solutions to the fractional Brezis-Nirenberg problems on bounded domain.Comment: 29 pages, Typos are fixed, Intro and refereces are extende

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo